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Abstract
Objective: Functional studies show that disruption of endothelial surface layer (ESL) is accompanied by enhanced sensitivity
of the vasculature towards atherogenic stimuli. However, relevance of ESL disruption as causal mechanism for vascular
dysfunction remains to be demonstrated. We examined if loss of ESL through enzymatic degradation would affect vascular
barrier properties in an atherogenic model.
Methods: Eight week old male apolipoprotein E deficient mice on Western-type diet for 10 weeks received continuous
active or heat-inactivated hyaluronidase (10 U/hr, i.v.) through an osmotic minipump during 4 weeks. Blood chemistry and
anatomic changes in both macrovasculature and kidneys were examined.
Results: Infusion with active hyaluronidase resulted in decreased ESL (0.3260.22 mL) and plasma volume (1.0360.18 mL)
compared to inactivated hyaluronidase (0.5260.29 mL and 1.2860.08 mL, p,0.05 respectively).Active hyaluronidase
increased proteinuria compared to inactive hyaluronidase (0.2760.02 vs. 0.1560.01 mg/mg protein/creatinin, p,0.05)
without changes in glomerular morphology or development of tubulo-interstitial inflammation. Atherosclerotic lesions in
the aortic branches showed increased matrix production (collagen, 3265 vs. 1863%; glycosaminoglycans, 1165 vs.
0.160.01%, active vs. inactive hyaluronidase, p,0.05).
Conclusion: ESL degradation in apoE deficient mice contributes to reduced increased urinary protein excretion without
significant changes in renal morphology. Second, the induction of compositional changes in atherogenic plaques by
hyaluronidase point towards increased plaque vulnerability. These findings support further efforts to evaluate whether ESL
restoration is a valuable target to prevent (micro) vascular disease progression.
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Introduction
Traditional risk factors, including dyslipidemia, diabetes,
hypertension and smoking, directly impact upon the vessel wall,
leading to accelerated atherogenesis [1]. The endothelial surface
layer (i.e., or the glycocalyx) forms a negatively charged barrier
limiting the leakage of charged (macro)molecules into the vessel
wall [2]. In animal models, we recently substantiated that the
morphology of endothelial surface layer is indeed modified at areas
with increased atherosclerosis risk [3]. Such endothelial surface
layer perturbation was accompanied by a local increased intima-
to-media ratio. While endothelial surface layer volume depends on
the balance between biosynthesis and shedding of its components
[4], interdepence of intermingled glycosaminoglycans on the
endothelial cell surface was demonstrated by treatment of murine
carotid artery vessel segments with hyaluronidase [5]. Hyaluron-
idase not only affected the amount of surface hyaluronan but also
resulted in a reduced heparan sulfate surface coverage. These
findings have fueled the concept that endothelial surface layer
disruption may in fact be a causal factor promoting atherogenesis
[2]. Previous studies have demonstrated a crucial role of
endothelial surface layer in development of both macro- as well
as microvascular endothelial dysfunction [6–8]. Macrovascular
endothelial surface layer perturbation is associated with the onset
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thrombocytes [6,9,10] as well as impaired nitric oxide release
[8,11]. In parallel, enzymatic removal of endothelial surface layer
more than doubled albumin flux through cultured glomerular
endothelial cells and kidney segments, lending further support to
the active role of endothelial surface layer in maintaining the
glomerular barrier [12–14]. In the present study, we report the
effect of prolonged enzymatic degradation of the endothelial
surface layer in vivo during the early process of atherogenesis in
apoE knockout (apoE
2/2) mouse on a Western-type diet
containing 0.25% cholesterol [15]. We hypothesized that
increased degradation of the endothelial surface layer early on in
the development of atherosclerosis might accelerate disease
progression. Systemic blood volume parameters are estimated,
together with cholesterol-, triglycerides-, and IL-6 levels to
investigate systemic changes upon chronic damage to the
endothelial surface layer. Macrovascular changes were determined
by measurement of the plaque area and composition of two vessels
branching from the aortic arch, i.e. the innominate- and left
subclavian artery. In addition, micro vascular changes were
determined in the kidney through possible morphologic changes
and by estimating urine protein/creatinin ratio as a function of
renal barrier properties.
Methods
Mice and Experimental Groups
All experiments were performed using eight week old male
(apoE
2/2) mice on C57Bl/6 background (Charles River), random-
ly divided into 5 groups. One group was fed a standard rodent
chow (NC; Sniff R/M-H, Germany) for 6 weeks (pre-Hyaluron-
idase infusion group, n=6), after which systemic volume
measurements, blood sampling and histology were performed.
The other 4 groups of mice were put on a high fat-, high
cholesterol diet containing 15% cacao butter, 0.25% cholesterol,
40.5% sucrose, 10% corn starch, 1% corn oil, and 5.95% cellulose
(HFC; diet-W, Hope farms, the Netherlands). At 14 weeks of age
mice on HFC received an osmotic minipump and mouse jugular
catheter (Alzet, Cupertino, CA) containing active- (n=15) or
inactive (n=15) testicular hyaluronidase (bovine testis, Sigma-
Aldrich). At 18 weeks of age systemic volume measurements, blood
sampling, urine collection and histology were performed. In
addition, apoE
2/2 mice were put on HFC alone for 6- (n=12) or
10 (n=6) weeks as control on the process of diet induced
atherogenesis. The experimental protocol was approved by the
local Animal Ethical Committee of Maastricht University (AEC
protocol number 2007-031) and all animal work was performed in
compliance with the Dutch government guidelines.
Hyaluronidase solution
Hyaluronidase (40 U/mL in saline) was injected into an osmotic
minipump which releases its content at a rate of 0.25 mL/hr
(10 U/hr) into the right jugular vein for at least 4 weeks. In
parallel, heat-inactivated hyaluronidase (boiled for 30 minutes at
90uC, centrifuged at 3000 rpm and passed through a 0.22 mm
filter to remove degraded protein aggregates) was used as control.
Anesthesia was performed using 1.6–2.0% isoflurane (Abbott) in
air. Activity of hyaluronidase was determined as previously
described using substrate gel electrophoresis [16]. In a subset of
mice, antibody induction against infused hyaluronidase was
evaluated. Therefore, serum samples were incubated with bovine
hyaluronidase (100 U/mL, 1 hr at 37uC; block 3% goat milk in
PBS) for 1 hr at 37uC. Serum of naı ¨ve mice and mouse-anti-rat
hyaluronidase antibody (10 mg/mL anti-hyaluronidase PH 20,
Abcam) were used as negative- and positive control, respectively.
Mouse-anti hyaluronidase antibodies (DAKO) were used in
combination with a color reaction using OPD/H2O2 (OD
490 nm).
Biochemical parameters
Mice were fasted for at least two hours before collecting blood.
Plasma lipoproteins were determined by FPLC in 80 mL of pooled
plasma samples per group. Triglycerides were measured from a
drop of blood from the tail before anesthesia using a blood
triglyceride- (Accutrend, Roche) test strip. Serum IL-6 was
measured using commercially available assay (Becton Dickinson).
For IL-6 measurements, a value of 1000 was assigned to levels
exceeding 1000 pg/mL for further calculations. Protein and
creatinin were determined in 100 mL of a pooled urine sample
from 4 individual animals per measurement on a Beckman
System.
Systemic tracer dilution determination
At 14 or 18 weeks of age, distribution volume determinations of
labeled erythrocytes and 40 kDa high molecular weight dextrans
were performed to assess systemic vascular red blood cell- (Vrbc),
plasma- (Vplasma), surface layer- (Vesl) and total vascular volume
(Vtotal) as previously described (20, 31, 36). In brief, RBC were
labeled with carboxyfluorescein diacetate, succinimidyl ester
(Invitrogen) and mixed with a stock solution (10 mg/ml) 40 kDa
Texas Red labeled dextran (Sigma). Following intravenous
injection of 0.1 mL of this tracer mix, blood samples were drawn
at 2, 5, 10, 15, 20 and 30 minutes. Ht was determined and plasma
was stored at 220uC. Circulating labeled RBC fraction was
determined using flow-cytometry (FACSCalibur; Becton Dick-
inson). Circulating Vplasma was calculated using the following
formula: ([1 – Ht] 6 Vrbc)/Ht (19, 20). In each plasma sample,
fluorescence was measured at 590 nm (D40-TR) using a spectro-
fluorophotometer (VICTOR; Perkin-Elmer, the Netherlands).
Concentration-time curves of D40-TR were fitted with a mono-
exponential function to determine initial tracer distribution
volume [17–19].
Histology and Immunohistochemistry
Following perfusion with 1% phosphate-buffered paraformal-
dehyde solution (pH 7.4, 10 minutes), the arterial tree and main
side branches and kidneys were removed and fixed overnight in
10% phosphate-buffered formalin. Renal tissue sections were
stained with periodic acid Schiff’s stain (PAS). Glomerular
mesangial macrophage infiltration was counted using Mac-3
staining (1:30, Becton Dickinson). Serial 4 mm sections of the
arterial tree were stained with HE. Atherosclerotic lesions were
classified as published [20]. Total plaque area and composition of
plaque were measured, including initial as well as advanced plaque
area. Further phenotyping, such as collagen- (Sirius red) and
glycosaminoglycan (Alcian blue) content, macrophage content
(Mac-3, 1:30) and macrophage size, were analyzed at parallel
tissue sections. All morphometric parameters were determined
using a microscope coupled to a computerized Leica morphom-
etry system.
Statistical analysis
Results are presented as mean 6 SD, morphometric data are
given as mean 6 SEM. Data were analyzed using the unpaired,
two-sided Student’s t test. A p-value of ,0.05 was considered
statistically significant. From PAS stained renal sections total
glomerular-, capillary tuft- and mesangial area were determined as
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kidney) and given in mm
2. The number (n) of nuclei and capillaries
per glomerulus were counted as the average of sub-cortical and
juxta medular- glomeruli (10 each/kidney). In addition, the
number of capillary microaneurysms- and macrophages/foam
cells per capillary tuft area were determined of 50 glomeruli per
kidney. Macrovascular lesion area was determined as the average
of four sections per mouse and given in mm
2 (610,000). Collagen-
and glycosaminoglycan content was expressed as positive area
relative to the total plaque area. Number of macrophages per
plaque area was determined and individual macrophage area was
calculated using number of macrophages per total plaque area.
Results
Endothelial surface layer in apoE
2/2 mice on atherogenic
diet alone
Bodyweight and plasma cholesterol levels of apoE
2/2 mice on
high fat atherogenic chow (HFC) for 10 weeks increased without
overt induction of serum IL-6 levels and apparent changes in
vascular blood volumes (table 1). Endothelial surface layer volume
(Vesl) decreased gradually from 0.5560.16 mL (21.666.3 mL/kg
BW, NC) to 0.4160.13 (15.864.8 mL/kg BW, 6 weeks HFC) and
0.3760.03 mL (12.163.5 mL/kg BW, 10 weeks HFC, p,0.05).
Endothelial surface layer in apoE
2/2 mice on atherogenic
diet and hyaluronidase infusion
After hyaluronidase infusion, the animals were heavier (28.06
2.3 and 28.962.3 g, hyaluronidaseact and hyaluronidaseinact,
respectively) compared to apoE
2/2 mice on NC but not to mice
on HFC alone for 10 weeks (table 1). As expected, atherogenic diet
induced dyslipidemia (table 1). In contrast to a HFC diet for 10
weeks alone, additional hyaluronidase (either active of inactivated)
administration resulted in significant increased serum IL-6 levels of
4146255 pg/mL (hyaluronidaseact) and 7156312 pg/mL (hya-
luronidaseinact) in combination with anti-hyaluronidase antibodies
in each group (0.32 and 0.74 g/L, p,0.05). As a result of the
combined atherogenic diet and inactive hyaluronidase infusion, a
decreased systemic Ht of 41.063.1% (table 1) was observed that
corresponded to a higher Vplasma of 1.2860.08 mL and a slightly
increased Vrbc of 0.8860.17 mL. In addition, although not
significant, Vesl was increased also to a volume of 0.5260.29 mL
(24.8615.0% of Vblood). However, when animals were infused
with active hyaluronidase (hyaluronidaseact), both Vesl of
0.3260.22 mL (p,0.05; 18.5612.9% of Vblood) and Vplasma of
1.0360.18 mL were reduced significantly compared to hyalur-
onidaseinact infusion. No effect on systemic Ht (42.963.2%) and
Vrbc (0.7760.14 mL) were observed.
Atherogenic progression in apoE
2/2 mice on
atherogenic diet and hyaluronidase infusion
After the full period of HFC and enzyme infusion, significant
advanced lesions developed within the aortic branching vessels
studied, i.e. innominate- (early start) and left subclavian artery
(later start) with intimal thickening, cholesterol accumulation and
necrotic cores in both hyaluronidase group (figures 1 and 2A).
Progression of atherogenic lesions were comparable to the lesions
found in apoE
2/2 mice on HFC for 10 weeks alone (figures 1A
and D), however within the less advanced subclavian arterial
branch, qualitative differences in atherogenic lesion content was
observed between mice infused with either active- or inactive
hyaluronidase. Plaque areas displayed a significant higher
percentage of both collagen- (1863% vs. 3265%; p,0.05) and
glycosaminoglycan (0.160.01% vs. 1165%) content in mice
infused with hyaluronidaseact as compared to hyaluronidaseinact
(figures 1 and 2B–C). In addition, longer stretches of the intimal
layer underneath these plaques were lost (see inset of figure 1F).
No change in macrophage number/area was observed in the
innominate artery (12.361.4 vs. 8.661.4 cells/10,000 mm
2 for
hyaluronidaseact and hyaluronidaseinact, respectively) and left
subclavian branch (15.662.9 vs. 12.561.6 cells/10,000 mm
2)
(figure 2D).
Table 1. Systemic parameters of apoE
2/2 mice on NC or HFC for 6- or 10 weeks w/o a final 4 week hyaluronidase infusion.
No enzyme Hyaluronidase
Systemic parameters NC HFC HFC Inactive Active
Age (weeks)Body 14 14 18 18 18
Body weight (g) 25.560.8 (6) 26.361.6 (12) 27.561.0
# (6) 28.961.9
# (14) 28.062.3
# (15)
Hematocrit (%) 45.562.0 (6) 46.061.2 (12) 45.362.2 (6) 41.063.1
#{ (14) 42.963.2 (15)
Cholesterol*
Total (mmol/L) 4.69 (1) 7.54 (1) 9.04 (1) 6.4261.76 (3) 6.7361.92 (3)
VLDL (mmol/L) 2.13 4.21 5.45 2.9060.92 3.1961.28
LDL (mmol/L) 2.04 2.88 3.17 3.0660.85 3.0760.62
HDL (mmol/L) 0.52 0.45 0.46 0.4660.09 0.4760.07
LDL/HDL 3.9 6.4 7.5 6.660.9 6.661.5
Triglycerides(mmol/L) ND ND ND 0.9060.09 (4) 1.0860.31 (5)
IL-6 (pg/mL) 146665 (6) 101640 (12) 159684 (5) 7156310
{1 (14) 4146255
{ (15)
Blood volumes
Vrbc (mL) 0.7160.03 (6) 0.7560.03
# (12) 0.7960.12 (6) 0.8860.17
# (14) 0.7760.14 (15)
Vplasma (mL) 0.8560.06 (6) 0.8960.06 (12) 0.9660.21 (6) 1.2860.30
#{1 (14) 1.0360.18
# (15)
Vblood (mL) 1.5660.07 (6) 1.6460.08 (12) 1.7560.32 (6) 2.1660.45
#1 (14) 1.8160.29 (15)
Vglx (mL) 0.5560.16 (6) 0.4160.13 (12) 0.3760.03
# (6) 0.5260.29
# 1 (14) 0.3260.22
# (15)
doi:10.1371/journal.pone.0014262.t001
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2/2 mice on atherogenic diet
and hyaluronidase infusion
Hyperlipidemia in aging apoE
2/2 mice has been shown to
induce several morphologic changes within the kidney [21].
Renal changes that occurred included elevated glomerular cell
number, glomerular matrix area, glomerular area, macrophages
in the mesangial area, deposition of extracellular matrix,
glomerular hyperplasia and capillary microaneurysms. ApoE
2/2
mice on a combined atherogenic diet for 10 weeks and
hyaluronidase infusion in the final 4 weeks displayed similar
changes in renal morphology (data not shown). No difference was
observed in renal morphology (table 2) between mice receiving
either hyaluronidaseact or hyaluronidaseinact (figure 3A and B)
with low amounts of glomerular foam cells (1.661.2 and.
0.660.2/50 glomeruli, hyaluronidaseact and hyaluronidaseinact,
respectively) and the appearance of microaneurysms (3.160.8 vs.
1.860.5/50 glomeruli, hyaluronidaseact and hyaluronidaseinact,
respectively). No tubulo-interstitial inflammation or vascular
pathology was seen.
Renal function in apoE
2/2 mice on atherogenic diet and
hyaluronidase infusion
Increased renal protein leakage was indicated from end-point
urine samples which showed that the protein/creatinin excretion
ratio (mg/mg) in apoE
2/2 mice on HFC alone for 10 weeks of 0.15
(pooled data) was higher than the ratio of 0.0760.04 found in
mice on NC, and before pump implant (see figure 4). Moreover,
the protein/creatinin excretion ratio was significantly increased up
to 0.2760.02 after infusion with hyaluronidaseact compared to the
raised excretion ratios for the 10 week HFC- and hyaluronida-
seinact group (0.1560.01, p,0.05).
Discussion
This study shows that chronic infusion of hyaluronidase
combined with a pro-atherogenic diet resulted in a decreased
endothelial surface layer. Loss of endothelial surface layer was
associated with increased proteinuria without changes in glomer-
ular morphology and without a significant effect on large vessel
atherosclerosis progression.
Endothelial surface layer and renal permeability
Hyaluronan glycosaminoglycans are important components of
the endothelial surface layer [5,12]. In line, infusion of
hyaluronidase has been demonstrated to effectively increase
microvascular permeability already 1 hour after a bolus injection
[22] whereas short term administration of hyaluronidase increased
perivascular macrophage accumulation following femoral artery
ligation [7]. In the present study, we found that 4 weeks of
hyaluronidase infusion had a profound effect on renal vascular
permeability. With comparable systemic inflammatory responses
upon either active or inactivated hyaluronidase infusion, the
increased renal protein leakage following active hyaluronidase
infusion most likely reflects endothelial surface layer perturbation.
This assumption concurs with published data underpinning the
importance of the endothelial surface layer to the glomerular
barrier in both animals and humans [23–25] and the significant
role of the glomerular endothelial surface layer for glomerular
barrier function [24,26]. Our data imply that glomerular
endothelial surface layer accounts for 50% of the glomerular
barrier; although the described effect is smaller than during acute
hyaluronidase exposure [26], this could be explained by the fact
that chronic hyaluronidase infusion results in compensatory
upregulation of endothelial GAG synthesis [2]. Interestingly, the
Figure 1. Photomicrographs of Sirius red-stained lesions within two major vessels branching from the aortic arch with a difference
in onset of atherogenic development. The (A, B, C) innominate- (early start) and (D, E, F) left subclavian artery (later start) from apoE
2/2 mice on
(A, D) a Western-type atherogenic diet alone, or in combination with (B, E) inactive- or (C, F) active hyaluronidase infusion, (inset F) Higher
magnification of Sirius red-stained lesion within the left subclavian artery from apoE
2/2 mice on a combined Western-type atherogenic diet and
active hyaluronidase infusion. Arrow head indicates absence of long stretches of the intimal layer underneath a plaque. Bar=0.2 mm, bar
inset=50 mm.
doi:10.1371/journal.pone.0014262.g001
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negatively charged heparan sulphates present in the glomerulus
[14,27]. More recently, van den Hoven et al argued against a
prominent role of such heparan sulphates in contributing to renal
permeability showing that over-expression of human-heparanase
in B6 mice resulted only in a low, but statistically significant,
higher level of albuminuria compared with controls [28].
Immunohistochemistry of kidney, spleen and liver sections from
these animals however, revealed that not all heparan sulphate
domains were lost. In our study, we used hyaluronidase, an
enzyme that also degrades glycosaminoglycans like chondroitin/
heparan sulphate besides hyaluronan, albeit to a lesser extent. By
this manner, degradation of multiple types of glycosaminoglycan
may have contributed to a more overt proteinuria in the present
study compared to a setting where only heparan sulphate was
degraded. Interestingly, in animals and patients with DM1, both
Figure 2. Atherogenic progression in the innominate- (white bars) and left subclavian (black bars) artery from apoE
2/2 mice on a
combined Western-type atherogenic diet with inactive- or active hyaluronidase infusion. (A) Distribution and level of advanced plaque
areas, given mm
2 610.000. Distribution and percentage of (B) collagen or (C) glycosaminoglycan within each plaque area. Distribution of individual
macrophage areas within each plaque area (D), given in mm
2.
doi:10.1371/journal.pone.0014262.g002
Table 2. Renal morphology in apoE
2/2 mice on HFC for 10 weeks with a final 4 week hyaluronidase infusion.
Hyaluronidase infusion
Glomerular area
(mm
2)
Capillary tuft area
(mm
2)
Mesangial area
(mm
2)
Nuclei/capillary tuft area
(n)
Capillaries/capillary tuft area
(n)
Inactive 42506118 (10) 2414675 (10) 512638 (10) 42.660.8 (10) 29.661.1 (10)
Active 39536155 (9) 23366112 (9) 516660 (9) 39.761.8 (9) 30.461.2 (9)
doi:10.1371/journal.pone.0014262.t002
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plasma hyaluronidase levels are elevated and associated with
decreased endothelial surface layer, underscoring potential clinical
relevance [25,29].
Endothelial surface layer and atherogenesis
Following our findings in patients with familial hypercholester-
olemia [30], we observed that infusion of hyaluronidase on top of
HFC resulted in a reduction of endothelial surface layer of at least
50% together with a reduction in total plasma volume. Decreased
endothelial surface layer invariably leads to increased permeability
of the endothelial barrier, which is considered to reflect increased
atherogenic vulnerability [31]. At the same time, both inactivated
and active hyaluronidase were associated with pro-inflammatory
changes [32]. Apart from these ‘pro-atherogenic’ changes, LDL
cholesterol levels were reduced upon hyaluronidase infusion in
mice. In this context, it is difficult to interpret the lack of an effect
of active hyaluronidase on atherogenesis per se. The inflammatory
activation in both hyaluronidase groups may have overruled any
specific impact of endothelial surface layer perturbation on
atherogenesis [33]. On the other hand, a pro-atherogenic effect
of endothelial surface layer perturbation may have been
neutralized by the reduced lipid burden in animals with active
hyaluronidase. The explanation for the reduced lipid levels may
relate to decreased uptake of dietary cholesterol as a result of
increased villous microcirculatory edema following hyaluronidase
infusion [34,35]. However, since we did not study gut specimens in
our study, this hypothesis deserves further study.
Finally, atherosclerotic plaques in mice infused with active
hyaluronidase did display higher glycosaminoglycan content. In
this respect, enzymatic exposure may trigger a reaction within
endothelial cells characterized by increased synthesis and accu-
mulation of glycosaminoglycans. As atherosclerotic plaques with
increased glycosaminoglycan content are more prone to rupture
[36], this may in fact point towards increased plaque vulnerability
following active hyaluronidase infusion [31]. In line, we previously
observed a linear relation between carotid intima media thickness
and increased plasma glycosaminoglycans [37].
Study limitations. Our study has several limitations. First, it
cannot be excluded that hyaluronidase remains stable in the
subcutaneous Alzet minipump, which may have resulted in an
underestimation of the effect of hyaluronidase during the 4 week
course of the experiment. Second, we found increased IL-6 plasma
levels upon both activated and inactivated hyaluronidase infusion.
This finding is in line with recently published data by de la Motte
et al [38], who showed that hyaluronidase per se can induce
increased synthesis of IL-6. Since heat-inactivation only affects the
catalytic domain of hyaluronidase (resulting in an altered protein
structure with reduced affinity for hyaluronan), the immunological
response cannot be prevented as the protein composition remains
identical. Consistent with the first limitation, this may also have
contributed to an underestimation of the magnitude of the ‘active’
hyaluronidase effect.
In summary, the association between enzyme-mediated endo-
thelial surface layer disruption and the induction of microalbu-
minuria emphasizes the generalized nature of endothelial surface
layer perturbation in the development of kidney related micro-
Figure 4. Renal protein leakage of apoE
2/2 mice on normal
chow (NC) or on a Western-type atherogenic diet (HFC) for 10
weeks or in combination with active- or inactive hyaluronidase
infusion, given as protein/creatinin excretion ratio (mg/mg).
Values are means 6 SD from end-point urine samples. Difference in
protein/creatinin ratio was assessed by means of two-sample t-test (2-
way). *P,0.05 of apoE
2/2 on HFC andinactive hyaluronidase vs.apoE
2/2
on NC; **P,0.05 of apoE
2/2 on HFC and active hyaluronidase vs.
apoE
2/2 on NC or apoE
2/2 on HFC and inactive hyaluronidase.
doi:10.1371/journal.pone.0014262.g004
Figure 3. Renal morphology of periodic acid Schiff’s stained (PAS) glomeruli of apoE
2/2 mice on a combined Western-type
atherogenic diet with (A) inactive- or (B)active hyaluronidase infusion. Bar=50 mm.
doi:10.1371/journal.pone.0014262.g003
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compositional changes in atherosclerotic lesions which could make
them more vulnerable to rupture. Further studies in humans are
underway addressing whether endothelial surface layer perturba-
tion indicates a poor outcome for kidney function and whether
restoration could provide a valuable target to prevent vascular
disease progression in general.
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